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Establishing risk of human 
experimentation with drugs
Administration of a chemical or biological compound to a 
human being is never without risk. Although knowledge about 
risks increases during the development process, risks are still 
present even when a substance is marketed. Particular care 
is necessary when a new drug is given to healthy volunteers 
without previous human testing. General principles for such 
research have been laid down in guidelines as early as 1983, 
and these were the basis for many current regulations. Most 
drugs at that time were small molecules with fairly well-
characterized, classic, pharmacological mechanisms. Th e 
proposed primary objectives for studies in healthy people 
were therefore to show pharmacological action in humans and 
the dose–response (or concentration–response) curve. Th is 
approach was judged safe and was lent support by fi ndings 
of available surveys. Over time, the main objectives for these 
trials changed — perhaps owing to the perceived safety of new 
traditional (small-molecule) medicines — to general tolerance 
and safety. Th e advent of increasingly potent and selective 
compounds for human-receptor systems led to situations in 
which predictability from animal data was diminishing. Th e 
fi rst substances in this category were small molecules with fairly 
foreseeable pharmacokinetics, and any unexpected adverse 
events were mostly fully reversible. Th e serious adverse events 
that arose during the fi rst administration of TGN1412, the 
so-called CD28 superagonistic antibody, have led to immediate 
reactions from diff erent regulators, ranging from a moratorium 
on CD28 research to rules about how many individuals should 
receive a new compound at the same time. It was concluded that 
special care should be given to ill-defi ned high-risk drugs. In a 
recent Lancet article, Kenter and Cohen proposed facilitating 
risk analysis of all new substances to be administered to human 
beings. Th is proposal is a very important mechanism for the 
whole medical community — in particular the renal community, 
which is struggling with diffi  cult patients who have to be treated 
with complicated drugs. (Lancet 2006; 368: 1387–1391)
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Control of capillary blood flow by 
pericytes
Capillary blood fl ow and pressure are assumed to be regulated 
by precapillary arterioles, because capillaries lack smooth 
muscle. However, many capillaries are surrounded at intervals by 
a cell type with contractile capabilities, the pericyte (see Figure). 
Peppiatt et al. now report that, at least in the brain, constriction 
and relaxation of pericytes induces corresponding changes 
to capillary diameter. Using capillaries in whole-retina and 
cerebellar slices, they examined pericyte and capillary responses 
to a variety of stimuli. Th eir results can be summarized as 
follows. First, neurotransmitters evoked pericyte-mediated 
capillary constriction in situ. Second, changes in capillary 
diameter were generated by pericytes, not endothelial cells. 
Th ird, decreasing pericyte contractile tone dilated capillaries: 
Ca2+ removal dilated retinal capillaries and glutamate dilated 
cerebellar capillaries through pericytes. Finally, in simulated 
ischemia, some pericytes constricted capillaries. Th e authors’ 
results establish pericytes as likely regulators of blood fl ow at 
the capillary level. Interestingly, only a low fraction of pericytes 
responded to neurotransmitters; this perhaps suggests a variable 
expression of transmitter receptors on pericytes at diff erent 
vascular sites. Th is would allow exquisite control of capillary 
fl ows and pressures. Th e results challenge the idea that arterioles 
are solely responsible for the control of capillary blood fl ow 
changes. (Nature 2006; 443: 700–704)
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Pericyte anatomy confers flow-regulating capability downstream of 
arterioles.
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Corneal avascularity is due to 
soluble VEGF receptor-1
Th e absence of blood vessels in the cornea, which is 
surrounded by the highly vascular conjunctiva, was already 
known to the ancients. Needless to say, corneal avascularity is 
required for optical clarity and optimal vision, and it has led 
to the cornea’s being widely used for validation of pro- and 
antiangiogenic therapeutic strategies. Corneal avascularity 
is remarkable given the presence in the cornea of vascular 
endothelial growth factor (VEGF)-A, a potent stimulator of 
angiogenesis, and the proximity of the cornea to vascularized 
tissues. Despite much recent work, the molecular foundations 
of corneal avascularity have remained unclear. In the last 
decade, many antiangiogenic molecules, such as angiostatin, 
endostatin, interleukin-1 receptor antagonist, pigment 
epithelium-derived factor, and thrombospondins, have 
been found in the cornea, leading to recognition of their 
actions as tumor suppressors, atherosclerotic plaque growth 
inhibitors, or modulators of wound healing. But none of 
these molecules is required for corneal avascularity, as mice 
defi cient in any of them retain normal corneal phenotypes. 
In a recent publication, Ambati et al. showed that the cornea 
expresses soluble VEGF receptor-1 (also known as sfl t-1) 
and that suppression of this endogenous VEGF-A trap by 
neutralizing antibodies, RNA interference, or Cre-lox-
mediated gene disruption abolishes corneal avascularity in 
mice. Further, they found that the spontaneously vascularized 
corneas of corn1 and Pax6+/– mice and Pax6+/– patients with 
aniridia are defi cient in sfl t-1, and that recombinant sfl t-1 
administration restores corneal avascularity in corn1 and 
Pax6+/– mice. Manatees, the only known creatures uniformly 
to have vascularized corneas, do not express sfl t-1, whereas 
the avascular corneas of dugongs, also members of the order 
Sirenia; elephants, the closest extant terrestrial phylogenetic 
relatives of manatees; and other marine mammals (dolphins 
and whales) contain sfl t-1. Th is indicates that it has a crucial, 
evolutionarily conserved role. Th e recognition that sfl t-1 is 
essential for preserving the avascular ambit of the cornea 
can rationally guide its use as a platform for angiogenic 
modulators, supports its use in treating neovascular diseases, 
and might provide insight into the immunological privilege 
of the cornea. (Nature 2006; 443: 993–997)
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Podocin and MEC-2 bind 
cholesterol to regulate the activity 
of associated ion channels
A screen for mutations in touch sensation of the worm 
Caenorhabditis elegans identifi ed several genes involved in 
this process, one of which turned out to be an ortholog of the 
mammalian amiloride-sensitive sodium channel, which is 
located in the collecting tubules of the kidney. Inactivation of 
another protein identifi ed in this screen, termed MEC-2, leads 
to defects in touch sensation by the worm. MEC-2 belongs 
to a large family of proteins that contain a domain called 
prohibitin; these are membrane proteins that regulate a variety 
of biological activities, in addition to mechanosensation, such 
as osmotic homeostasis, and cell signaling, but the molecular 
mechanism of this regulation is unknown. One member of 
this family is podocin, the protein whose mutation leads to 
steroid-resistant nephrotic syndrome. Podocin is located in 
the fi ltration barrier and is a podocyte-specifi c protein. Huber 
et al. found that both MEC-2 and podocin bind cholesterol 
in a manner that requires the prohibitin domain. Cholesterol 
appears to organize a patch of membrane that accumulates 
prohibitin binding domains as well as ion channels that bind 
to them, such as the amiloride-sensitive sodium channel 
of the worm. Remarkably, the authors showed that when 
podocin is the cholesterol-binding prohibitin domain protein, 
the channel is a calcium channel termed TRPC. Transient 
receptor potential channels (TRPs) are a large family of 
cation channels, one of whose members, TRPC6, was found 
to be the causative mutation in a family with focal segmental 
glomerulosclerosis (FSGS). Th e unexpected fi nding of the 
role of TRPC6 in the causation of FSGS is now made a little 
more understandable, since it associates with podocin, a 
known component of the slit diaphragm. Hence, it seems that 
cholesterol might organize the proteins of the slit diaphragm 
into a large protein complex. Th e authors also speculate that 
steroids other than cholesterol might function to organize this 
complex, and one intriguing hypothesis they present is that 
glucocorticoids might perform this function ‘chemically,’ that 
is, without the intervention of nuclear hormone receptors. 
Th ey also point out that it is intriguing that podocin mutations 
are associated with steroid-resistant nephrotic syndrome. 
(Proc Natl Acad Sci USA 2006; 103: 17079–17086)
Qais Al-Awqati
Knockdown of sflt-1 mRNA using RNA interference abolished corneal 
avascularity (left and middle), whereas control plasmid had no effect 
(right).
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